Effective T cell regeneration following high-dose chemotherapy rescued with CD34+ cell enriched peripheral blood progenitor cells in children

被引:10
作者
Heitger, A
Kern, H
Mayerl, D
Maurer, K
Nachbaur, D
Frühwirth, M
Fink, FM
Niederwieser, D
机构
[1] Univ Innsbruck Hosp, Dept Internal Med, Div Clin Immunol & Bone Marrow Transplantat, Innsbruck, Austria
[2] Univ Leipzig, Div Hematol & Oncol, Leipzig, Germany
[3] Univ Innsbruck, Childrens Hosp, A-6020 Innsbruck, Austria
关键词
CD34(+) enrichment; peripheral stem cell rescue; T cell reconstitution; children; solid tumours;
D O I
10.1038/sj.bmt.1701588
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The ex vivo enrichment for the CD34(+) cell fraction of PBPC, while it retains the capacity to restore haematopoiesis and potentially reduces a contamination by tumour cells, implements a depletion of T cells. To test whether such a setting adversely affects T cell reconstitution, we monitored T cells in four paediatric patients after CD34(+) selected PBPC transplantation. The dose of CD34(+) cells, which were enriched to 74%, median, was 7.1 x 10(6)/kg, median, that of T cells was 0.071 x 106/kg, median. The patients were homogenous with respect to features with a potential to effect T cell reconstitution (low median age, (3.5 years); stage TV malignant tumours in first CR, uncomplicated post-treatment course). The results of sequential FAGS analyses showed that by 9 months after treatment all four patients had recovered (1) a normal T cell count (CD3(+) cells 1434/mu l, median); (2) a normal CD4(+) cell count (816/mu l, median), while CD8(+) cells were recovered (>330/mu l) already by 3 months; (3) a normal CD4/CD8 ratio (1.8, median), as a result of an augmented growth of CD4(+) cells between 3 and 6 months (increase of CD4(+) cells 4.9-fold, median, CD8(+) cells 1.1-fold, median). Expansion of cells with a CD45RA(+) phenotype (thymus-derived T cells) predominated; from 3 to 6 months the increase of CD4(+)/CD45RA(+) T cells was WO-fold, that of CD4(+)/CD45RO(+) cells was 1.7-fold; CD8(+)/CD45RA(+) cells increased 9-fold, CD8(+)/CD45RO(+) cells increased 2.1-fold, indicating effective thymopoiesis. The findings demonstrate that in paediatric patients the setting of HD-CTX rescued with autologous CD34(+) selected PBPC per se is not predictive of an impaired T cell recovery. High thymic activity may be a key factor for the rapid restoration of T cells.
引用
收藏
页码:347 / 353
页数:7
相关论文
共 55 条
[11]  
Cela ME, 1996, BONE MARROW TRANSPL, V17, P243
[12]  
DEGAST GC, 1985, BLOOD, V66, P428
[13]   AGE-RELATED-CHANGES IN HUMAN-LYMPHOCYTE SUBSETS - PROGRESSIVE REDUCTION OF THE CD4 CD45R (SUPPRESSOR INDUCER) POPULATION [J].
DEPAOLI, P ;
BATTISTIN, S ;
SANTINI, GF .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1988, 48 (03) :290-296
[14]   G-CSF-MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS FOR ALLOGENEIC TRANSPLANTATION - SAFETY, KINETICS OF MOBILIZATION, AND COMPOSITION OF THE GRAFT [J].
DREGER, P ;
HAFERLACH, T ;
ECKSTEIN, V ;
JACOBS, S ;
SUTTORP, M ;
LOFFLER, H ;
MULLERRUCHHOLTZ, W ;
SCHMITZ, N .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (03) :609-613
[15]  
FAVROT M, 1983, CLIN EXP IMMUNOL, V54, P59
[16]  
FOOT ABM, 1993, BONE MARROW TRANSPL, V11, P7
[17]   AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PEDIATRIC WILMS-TUMOR - THE EXPERIENCE OF THE EUROPEAN BONE-MARROW TRANSPLANTATION SOLID TUMOR REGISTRY [J].
GARAVENTA, A ;
HARTMANN, O ;
BERNARD, JL ;
ZUCKER, JM ;
PARDO, N ;
CASTEL, V ;
DALLORSO, S ;
ADELBOST, Z ;
LADENSTEIN, R ;
CHAUVIN, F ;
PHILLIP, T .
MEDICAL AND PEDIATRIC ONCOLOGY, 1994, 22 (01) :11-14
[18]  
GOROCHOV G, 1994, BLOOD, V83, P587
[19]   DEVELOPMENTAL AND MATURATIONAL CHANGES IN HUMAN BLOOD LYMPHOCYTE SUBPOPULATIONS [J].
HANNET, I ;
ERKELLERYUKSEL, F ;
LYDYARD, P ;
DENEYS, V ;
DEBRUYERE, M .
IMMUNOLOGY TODAY, 1992, 13 (06) :215-218
[20]   Essential role of the thymus to reconstitute naive (CD45RA(+)) T-helper cells after human allogeneic bone marrow transplantation [J].
Heitger, A ;
Neu, N ;
Kern, H ;
PanzerGrumayer, ER ;
Greinix, H ;
Nachbaur, D ;
Niederwieser, D ;
Fink, FM .
BLOOD, 1997, 90 (02) :850-857